Volume 22, Number 9—September 2016
CME ACTIVITY - Synopsis
Treatment Outcomes for Patients with Extensively Drug-Resistant Tuberculosis, KwaZulu-Natal and Eastern Cape Provinces, South Africa
Charlotte L. Kvasnovsky
, J. Peter Cegielski, and Martie L. van der Walt
, J. Peter Cegielski, and Martie L. van der Walt
Table 2
Treatment and treatment outcomes for patients with extensively drug-resistant tuberculosis, KwaZulu-Natal and Eastern Cape Provinces, South Africa, 2006–2010*
| Characteristic | Total, n = 355 | HIV negative, n = 124 | HIV positive, receiving ARVs, n = 114 | HIV positive, not receiving ARVs, n = 79 | HIV positive, ARV status unknown, n = 27 | p value† |
|---|---|---|---|---|---|---|
| No. drugs in treatment regimen | 5 (5–6) | 5 (5) | 5 (5–6) | 5 (5) | 5 (5–6) | 0.56 |
| Effective drug treatment | 109 (31.7) | 29 (26.6) | 46 (42.2) | 32 (29.4) | 2 (1.8) | 0.0004 |
| Any culture conversion | 77 (22.4) | 28 (22.6) | 33 (29.0) | 12 (15.2) | 4 (14.8) | 0.11 |
| Alive after 2 y treatment | 96 (27.9) | 46 (37.1) | 30 (26.3) | 18 (22.8) | 2 (7.4) | 0.007 |
| Favorable treatment outcome | 34 (10.3) | 15 (12.3) | 13 (12.2) | 5 (6.6) | 1 (4.0) | 0.37 |
*Values are median (interquartile range) or no. (%). p values in bold are statistically significant. ARVs, antiretroviral drugs.
†Calculation excluded 11 patients with unknown HIV status.
Page created: August 11, 2016
Page updated: August 11, 2016
Page reviewed: August 11, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.